{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-086616","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2022-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.186908+00:00","generated_at":"2026-06-26T16:19:32.223950+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Phathom appoints Molly Henderson as CFO/Chief Business Officer; Guzzo to depart","bullets":["Molly Henderson, former Urogen Pharma CFO, becomes Chief Financial and Business Officer effective April 5, 2022.","Henderson's base salary $480,000; target bonus 45% of salary; receives options for 100k shares and 20k RSUs.","Anthony Guzzo, Chief Accounting Officer and acting principal financial officer, to depart around Aug 15, 2022.","Guzzo's departure not due to disagreement; vesting extended for certain PSVs and option exercise period to Dec 31, 2022.","Henderson replaces Guzzo as principal financial and accounting officer effective April 5, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-086616","json":"https://secwatch.observer/filing/0001193125-22-086616.json","markdown":"https://secwatch.observer/filing/0001193125-22-086616.md","text":"https://secwatch.observer/filing/0001193125-22-086616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/0001193125-22-086616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/d306197d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T16:19:32.223950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7414ac9727","claim":"Molly Henderson was appointed as Chief Financial and Business Officer at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"On March 22, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) announced the appointment of Molly Henderson, 51, as its Chief Financial and Business Officer effective April 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522086616/0001193125-22-086616-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}